Efficient CRISPR-mediated mutagenesis in primary immune cells using CrispRGold and a C57BL/6 Cas9 transgenic mouse line

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Van Trung Chu - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Robin Graf - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Tristan Wirtz - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Timm Weber - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Jeremy Favret - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Xun Li - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Kerstin Petsch - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Ngoc Tung Tran - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Michael H Sieweke - , Max Delbrück Center for Molecular Medicine (MDC), Marseille-Luminy Immunology Center (CIML), Aix-Marseille Université, INSERM - Institut national de la santé et de la recherche médicale, French National Centre for Scientific Research (CNRS) (Author)
  • Claudia Berek - , German Rheumatism Research Centre Berlin (Author)
  • Ralf Kühn - , Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Klaus Rajewsky - , Max Delbrück Center for Molecular Medicine (MDC) (Author)

Abstract

Applying clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9)-mediated mutagenesis to primary mouse immune cells, we used high-fidelity single guide RNAs (sgRNAs) designed with an sgRNA design tool (CrispRGold) to target genes in primary B cells, T cells, and macrophages isolated from a Cas9 transgenic mouse line. Using this system, we achieved an average knockout efficiency of 80% in B cells. On this basis, we established a robust small-scale CRISPR-mediated screen in these cells and identified genes essential for B-cell activation and plasma cell differentiation. This screening system does not require deep sequencing and may serve as a precedent for the application of CRISPR/Cas9 to primary mouse cells.

Details

Original languageEnglish
Pages (from-to)12514-12519
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America : PNAS
Volume113
Issue number44
Publication statusPublished - 1 Nov 2016
Peer-reviewedYes
Externally publishedYes

External IDs

PubMedCentral PMC5098665
Scopus 84994045496

Keywords

Keywords

  • Animals, B-Lymphocytes/metabolism, CRISPR-Cas Systems, Cell Differentiation/genetics, Cells, Cultured, Gene Editing/methods, Lymphocyte Activation/genetics, Macrophages/metabolism, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Mutagenesis, Plasma Cells/metabolism, Reproducibility of Results, T-Lymphocytes/metabolism

Library keywords